Shares of CryoPort, Inc. (NASDAQ:CYRX) have earned a consensus broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has assigned a strong buy rating to the company. CryoPort’s rating score has declined by 50% in the last 90 days as a result of various analysts’ upgrades and downgrades.

Brokers have set a one year consensus price objective of $4.83 for the company and are anticipating that the company will post ($0.08) earnings per share for the current quarter, according to Zacks. Zacks has also assigned CryoPort an industry rank of 156 out of 265 based on the ratings given to its competitors.

Several brokerages recently issued reports on CYRX. Cowen and Company began coverage on CryoPort in a research note on Friday. They issued an “outperform” rating and a $5.50 price objective on the stock. Needham & Company LLC increased their target price on CryoPort from $3.50 to $4.50 and gave the company a “buy” rating in a research report on Thursday, June 1st. Finally, ValuEngine raised CryoPort from a “sell” rating to a “hold” rating in a research report on Thursday, May 11th.

Shares of CryoPort (CYRX) traded down 2.78% during midday trading on Monday, hitting $4.55. The stock had a trading volume of 79,740 shares. The company’s market cap is $109.09 million. The company’s 50 day moving average is $3.35 and its 200 day moving average is $3.12. CryoPort has a 52-week low of $1.50 and a 52-week high of $4.75.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Thursday, May 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. CryoPort had a negative return on equity of 104.79% and a negative net margin of 137.99%. The company had revenue of $2.71 million for the quarter, compared to analysts’ expectations of $2.59 million. On average, analysts anticipate that CryoPort will post ($0.72) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at

About CryoPort

Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.

Get a free copy of the Zacks research report on CryoPort (CYRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for CryoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc. and related companies with's FREE daily email newsletter.